# Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

> **NCT02445872** · PHASE2 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 80 (estimated)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting
- Lung Cancer

## Interventions

- **DRUG:** Aprepitant
- **DRUG:** Palonosetron
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02445872
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2015-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02445872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02445872, "Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02445872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*